Cyclooxygenase-2 Inhibitors in Cancer Prevention and Treatment

  • Jaime L. Masferrer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 532)


By inhibiting the cyclooxygenase (COX) enzyme, NSAIDs block the synthesis of prostaglandins, which are important mediators of multiple physiologic and pathophysiologic processes. There are 2 COX isoforms. COX-1 maintains physiologic processes, and its inhibition may be associated with undesirable effects. COX-2 is induced in response to growth factors, cytokines, and tumor promoters and is responsible for the therapeutic activity of NSAIDs. Epidemiologie, preclinical, and clinical evidence gathered over the last 15 years demonstrates that, in addition to their anti-inflammatory and analgesic properties, NSAIDs, particularly specific COX-2 inhibitors, such as celecoxib, also have a role in preventing tumor initiation and development.


Cancer Prevention Familial Adenomatous Polyposis Esophageal Carcinoma Transitional Cell Carcinoma Colorectal Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gridley, G., McLaughlin, J.K., Ekbon, A, et al.: Incidence of cancer among patients with rheumatoid arthritis. J Natl. Cancer Inst. (1993) 85:307–311.PubMedCrossRefGoogle Scholar
  2. 2.
    Sandler, RS: Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. Lippincott-Raven Publishers (1996) Philadelphia, PA.Google Scholar
  3. 3.
    Suh, O, Mettlin, C, Petrelli, NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer (1993) 72:1171–1177.PubMedCrossRefGoogle Scholar
  4. 4.
    Marneit, LJ: Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Preventive Med (1995) 24:103–106.CrossRefGoogle Scholar
  5. 5.
    Reeves, MJ, Newcomb, PA, Trentham-Dietz, A, Storer, BE, Remington, PL: Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol. Biomark. Prey. (1996) 5:955–960.Google Scholar
  6. 6.
    Rosenberg, L, Palmer, JR, Zauber, GA, Warshauer, ME, Stolley, PD, Shapiro, S: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J. Natl. Cancer Inst. (1991) 83:355–358PubMedCrossRefGoogle Scholar
  7. 7.
    Peleg, II, Maibach, HT, Brown, SH, Wilcox, CM: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med. (1994) 121:394–399.Google Scholar
  8. 8.
    Muscat, JE, Stellman, SD, Wynder, EL: Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer (1994) 74:1847–1854.PubMedCrossRefGoogle Scholar
  9. 9.
    Morgan, G: Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Gut (1996) 38:646–648.PubMedCrossRefGoogle Scholar
  10. 10.
    Thun, MJ, Namboodiri, MM, Calle, EE, Flanders, WD, Heath, CW JR: Aspirin use and risk of fatal cancer. Cancer Res. (1993) 53:1322–1327.PubMedGoogle Scholar
  11. 11.
    Schreinemachers, DM, Everson, RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology (1994) 5:138–146.PubMedCrossRefGoogle Scholar
  12. 12.
    Thun, MJ: NSAID use and decreased risk of gastrointestinal cancers. Gastroenterology Clinics of North America (1996) 25:333–348.PubMedCrossRefGoogle Scholar
  13. 13.
    Farrow, DC, Vaughan, TL, Hansten, PD, et al.: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epid. Biom. & Prev. (1998) 7:97–102.Google Scholar
  14. 14.
    Funkhouser, EM, Sharp, GB: Aspirin and reduced risk of esophageal carcinoma. Cancer (1995) 76:1116–1119.PubMedCrossRefGoogle Scholar
  15. 15.
    Giovannucci, E, Egan, KM, Hunter, DJ et al.: Aspirin and the risk of colorectal cancer in women. N. Eng. J. Med. (1995) 333:609–614.CrossRefGoogle Scholar
  16. 16.
    Rigas, B, Goldman Giovannucci, E, Rimm, EB, Stampfer, MJ, Coldtiz, GA; Ascherio, A, Willett, W C: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. (1994) 121:241–246.Google Scholar
  17. 17.
    Bennett, A, Berstock, DA, Raja, B, Stanford, IF: Survival time after surgery is inversely related to amounts of prostaglandin extracted from human breast cancer. Br. J. Pharmacol. (1979) 66:451P.Google Scholar
  18. 18.
    Pugh, S, Thomas, GA: Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut (1994) 35:675–678.PubMedCrossRefGoogle Scholar
  19. 19.
    Rigas, B, Goldman, IS, Levine, L: Altered eicosanoid levels in human colon cancer. J Lab. Clin. Med. (1993) 122:518–523.PubMedGoogle Scholar
  20. 20.
    Yang, VW, Shields, JM, Hamilton, SR et al.: Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. (1998) 58:1750–1753.PubMedGoogle Scholar
  21. 21.
    O M, Dinchuk JE, Kargman SL et al.: Suppression of intestinal polyposis in APC-delta-716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 87:803–809.PubMedCrossRefGoogle Scholar
  22. 22.
    Labayle, D., Fisher, D., Vieln, P et al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 101:635–639.PubMedGoogle Scholar
  23. 23.
    Yoshimi, N, Kawabata, K, Hara, A: Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn. J. Cancer Res. (1997) 88:1044–1051.Google Scholar
  24. 24.
    Reddy BS, Rao, CV, Seibert,K: Evaluation of cyclooxygenase-2 inhibito for potential chemopreventive properties in colon carcinogenesis. Cancer Res. (1996) 56:4566–4569.PubMedGoogle Scholar
  25. 25.
    Kawamori, T, Rao, CV, Seibert, K, Reddy, BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. (1998) 58:409–412.PubMedGoogle Scholar
  26. 26.
    Wilson, KT, FU, S, Ramanujam, KS, Meltzer, SJ: Increased expression of inducible nitric oxide and cyclooxygenase -2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res. (1998) 58:2929–2934.PubMedGoogle Scholar
  27. 27.
    Soslow, RA, Dannenberg, Ai, Rush, D, et al.: COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer (2000) in review. 107:1183–1188Google Scholar
  28. 28.
    Eeberhart, CE, Coffey, RJ, Radhika, A, et al.: Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 107:1183–1188.Google Scholar
  29. 29.
    Hida, T, Tayabe, Y, Achiwa, H, et al.: Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. (1998) 58:3761–3764.PubMedGoogle Scholar
  30. 30.
    Mohammed, SI, Knapp, DW, Bostwick, DG: Expression of cyclooxygenase-2 in human invasive transitional cell carcinoma of the urinary bladder. Cancer Research Adv. In Brief (1999) 59:5647–5650.Google Scholar
  31. 31.
    Buckman, SY, Gresham, A, Hale, P, et al.: COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis (1998) 19(5):723–729.PubMedCrossRefGoogle Scholar
  32. 32.
    Koki, AT, Leahy, KM, Masferrer, JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp. Opin. Invest. Drugs (1999) 8(10):1623–1638.CrossRefGoogle Scholar
  33. 33.
    Seed, MP:. Angiogenesis inhibition as a drug target for disease: an update Exp. Opin. Invest. Drugs. (1996) 5(12):1617–1637.Google Scholar
  34. 34.
    Form, DM, Auerbach R: PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. (1983) 172(2):214–218.PubMedGoogle Scholar
  35. 35.
    Rolland, PH, Martin, PM, Jacquemeier, J, Rolland, AM, Togs, M: Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Institute (1980) 64:1061–1070.Google Scholar
  36. 36.
    Karmali, RA, Welts, S, Thaler, HT, Lefevre, F: Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br. J. Cancer (1983) 48:689–696.PubMedCrossRefGoogle Scholar
  37. 37.
    Fulton, AM, Ownby, HE, Frederick, J, Brennan, MJ: Relationship of tumor prostaglandin levels to early recurrence in women with primary breast cancer: a clinical update. Invasion Metastasis (1986) 6:8394.Google Scholar
  38. 38.
    Bennett, A, Berstock, DA, Raja, B, Stanford, IF: Survival time after surgery is inversely related to amounts of prostaglandin extracted from human breast cancer. Br. J. Pharmacol. (1979) 66:451P.Google Scholar
  39. Form, DM, Auerbach R: PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. (1983) 172(2):214–218.PubMedGoogle Scholar
  40. 40.
    C G, Boyle JO, Yang EK et al.: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. (1999) 59: 991–994.PubMedGoogle Scholar
  41. 41.
    Tucker ON, Dannenberg AJ, Yang EK et al.: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. (1999) 59:987–990.PubMedGoogle Scholar
  42. 42.
    Gupta, S, Srivastava, M, Ahmad, N, Bostwick, DG, Mukhtar, H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 42:73–78.PubMedCrossRefGoogle Scholar
  43. 43.
    Hwang, D, Scollard, D, Byrene, J, Levine. E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Insti. (1998) 90:455–460.CrossRefGoogle Scholar
  44. 44.
    Parrett, ML, Harris, RE, Joarder, FS, Ross, MS, Clausen, KP, Robertson, FM: Cyclooxygenase-2 gene expression in human breast cancer. Int. J. of Oncol. (1997) 10:503–507.Google Scholar
  45. 45.
    Wolff, H. Saukkonen, KL, Anttila, S, Karjalainen, A, Vainio, H, RISTIMAKI, A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. (1998) 58:4997–5001.PubMedGoogle Scholar
  46. 46.
    Toyoaki, H, Yatabe, Y, Achiva, H, et al.: Increased cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. (1998) 58:3761–3764.Google Scholar
  47. 47.
    Zimmerman, KC, Sarbia, M, Weber, A, Borchard, F, Gabbert, H, Schror, K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. (1999) 59:198–204.Google Scholar
  48. 48.
    Knapp, DW, Glickman, NW, Denicola, DB, Bonney, PL, Lin, TL, Glickman, LT: Naturally-occurring canine transitional cell carcinoma of the urinary bladder, a relevant model of human invasive bladder cancer. Urologic Oncology (1999) (in press).Google Scholar
  49. 49.
    Mohammed, S., Lafayette, W, Foster, R et al.: Expression of cyclooxygenase COX-I and COX-2 in human invasive transitional cell carcinoma of the urinary bladder. American Urological Association Meeting, Dallas, TX (1999)Google Scholar
  50. 50.
    Lundholm, K, Gelin, J, Hyltander, A, Lonnroth, C, Sandstrom, R, Svaniger, G: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res., (1994) 5:5602–5606.Google Scholar
  51. 51.
    Masferrer, JL, Leahy, K, Koki, AT, Zweifel, BS, Settle, SL, Woerner, BM, Edwards, DA, Flickinger, AG, Moore, RJ, Seiebert, K: Angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. (2000) Cancer Res. 60(5):1306–1311.PubMedGoogle Scholar
  52. 52.
    Tsuji, M, Dubois, RN: Alterations in cellular adehision and apoptosis in epithelial-cells overexpressing prostaglandin-endoperoxide synthase-2. Cell (1995) 83:493–501.CrossRefGoogle Scholar
  53. 53.
    Milas, L, Kishi, K, Hunter, N, Masferrer, JL, Tofilon, PJ: Enhancement of tumor response to g-irradiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl. Cancer Inst. (1999) 91:1501–1504.PubMedCrossRefGoogle Scholar
  54. 54.
    Kishi, K, Petersen, S, Petersen, C, Hunter, N, Masferrer, JL, Tofilon, PJ, Milas, L: Preferential enhancement of tumor radioresponse by a COX-2 inhibitor. Cancer Res. (2000) 60:1326–1331.PubMedGoogle Scholar
  55. 55.
    Tsuji, M, Kawano, S, Tsuji, S, Sawahoka, H, Hori, M, Duboise, RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. (1998) Cell 93:705–716.PubMedCrossRefGoogle Scholar
  56. 56.
    Sheng, H, Williams, CS, Shao, J, Liang, P, Duboise, RN, Beauchamp, RD: Induction ofcyclooxygenase2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. (1998) J Biol. Chem. 273:22120–22127.PubMedCrossRefGoogle Scholar
  57. 57.
    Tsuji, M, Kawano, S, Duboise, RN: Cyclooxgynase-2 expression in human colon cancer cells increases metastatic potential. (1997) Proc. Natl. Acad. Sci. USA 94:3336–3340.CrossRefGoogle Scholar
  58. 58.
    Huang, M, Stolina, M, Sharma, S, Mao, JT, Zhu, L, Miller, PW, Wollman, J, Herschman, H, Dubinett, SM: Non-small cell lung cancer cyclooxygenase-2 dependent regulation of interleukin-10 and down-regulation of interleukin-12 production. (1998) Cancer Res. 58:1208–1216.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Jaime L. Masferrer
    • 1
  1. 1.Science Fellow, Pharmacia Corporation700 Chesterfield parkwaySt. LouisUSA

Personalised recommendations